Observational Health Data Analysis of Cardiovascular Adverse Events in Prostate Cancer Patients

Strategic Insights -

Research at University College London's Division of Surgery and Interventional Sciences has analyzed the real-world data of patients with metastatic hormone-sensitive prostate cancer (mHSPC) to estimate the risks of cardiovascular adverse events (AEs). The study, published in European Urology Focus, utilized the PIONEER Big Data platform to define cohorts and calculate the incidence rates of AEs. The data included 90,087 mHSPC patients, with a substantial comorbidity burden and a high rate of cardiovascular AEs reported.

Key Takeaways:

  • The study analyzed data from 90,087 patients with mHSPC, treated with androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPI) + docetaxel (DOC), ADT + ARPI, ADT + DOC, or ADT alone.
  • The study found that the highest incidence rates of AEs were for acute cardiac events (ADT), cerebral events (ADT + ARPI), thromboembolism (ADT + ARPI), chronic heart failure (ADT), and hypertension (ADT + ARPI + DOC).
  • The 3-year acute cardiac event-free survival rate ranged from 79% to 97%, and the 3-year mean cumulative function (MCF) for acute cardiac events was up to 0.33.
  • The study reported that patients with mHSPC had a substantial comorbidity burden, often exceeding that reported in clinical trials, alongside a high rate of cardiovascular AEs.
  • The study highlighted important heterogeneity in real-world, observational mHSPC data.

Statistics:

  • 90,087 patients with mHSPC were included in the study.
  • The study reported that diabetes was present in up to 33%, heart failure in 17%, obesity in 25%, and kidney impairment in 26% of men.
  • The highest incidence rates of AEs were as follows: 115 cases (ADT) for acute cardiac events, 403 (ADT + ARPI) for cerebral events, 214 (ADT + ARPI) for thromboembolism, 34 (ADT) for chronic heart failure, and 143 (ADT + ARPI + DOC) for hypertension.
  • The 3-year acute cardiac event-free survival rate ranged from 79% to 97%.
  • The 3-year MCF for acute cardiac events was up to 0.33.

Sources:

  • NewsRx. Studies from University College London (UCL) Provide New Data on Prostate Cancer (Observational Health Data Analysis of the Cardiovascular Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big ...). Clinical Trials Week. October 20, 2025; p 871.
  • European Urology Focus. Observational Health Data Analysis of the Cardiovascular Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform. 2025.